Since May, many places in China have successively implemented the results of centralized insulin collection. Listed companies have accelerated the pace of new product development and approval. Post date May 12, 2022 — 20:59 Post Lock Read More A-Share Toutiao Listed Company (5.10) Stock Financial Industry Post date May 10, 2022 — 00:03 Post Lock Read More On the evening of May 9th, Shanghai and Shenzhen listed companies announced the latest express of major events_ Oriental Fortune Net Post date May 9, 2022 — 19:55 Post Lock Read More Tonghua Dongbao: As some of the company's R&D projects have successively reached the capitalization conditions, the proportion of the company's R&D capitalization expenditure has increased in recent years. Post date May 5, 2022 — 15:16 Post Lock Read More Tonghua Dongbao: The company is confident to maintain the steady growth of second-generation insulin this year and will focus on the third-generation insulin market. Post date May 5, 2022 — 15:16 Post Lock Read More Tonghua Dongbao: As some of the company's R&D projects have successively reached the capitalization conditions, the proportion of the company's R&D capitalization expenditure has increased in recent years. Post date May 5, 2022 — 15:15 Post Lock Read More Tonghua Dongbao: The company accounted for 26.11% of the agreed procurement volume in Henan Province, ranking first in every economic network. Post date May 5, 2022 — 15:11 Post Lock Read More Tonghua Dongbao: In Henan Province, the company accounted for 26.11% of the agreed procurement volume of centralized procurement, occupying the first place – yqqlm Post date May 5, 2022 — 15:11 Post Lock Read More Tonghua Dongbao: In Henan Province, the company accounts for 26.11% of the agreed procurement volume of centralized procurement, occupying the first place_ Oriental Fortune Net Post date May 5, 2022 — 15:10 Post Lock Read More Can insulin "price-for-volume" bring new revenue? Before the answer was revealed, Gan & Lee Pharmaceutical went overseas to find new profit growth points. Post date May 1, 2022 — 00:19 Post Lock Read More The truth in the financial report: Can the "price-for-volume" of insulin in the pharmaceutical industry bring about new revenue growth? Before the answer was revealed, Gan & Lee Pharmaceutical went overseas to find new profit growth points. Post date May 1, 2022 — 00:16 Post Lock Read More Can insulin "price-for-volume" bring new revenue? Before the answer was revealed, Gan & Lee Pharmaceutical went overseas to find new profit growth points_Oriental Fortune Net Post date April 30, 2022 — 22:19 Post Lock Read More The truth in the financial report: Can the "price-for-volume" of insulin in the pharmaceutical industry bring about new revenue growth? Before the answer was revealed, Gan & Lee Pharmaceutical went overseas to find new profit growth points. Post date April 30, 2022 — 22:16 Post Lock Read More The truth in the financial report: Can the "price-for-volume" of insulin in the pharmaceutical industry bring about new revenue growth? Before the answer was announced, Gan & Lee Pharmaceutical went overseas to find new profit growth points Post date April 30, 2022 — 22:16 Post Lock Read More Thousands of listed companies have collectively disclosed their performance, and these 28 stocks are most favored by institutions! Many industry leaders are optimistic about the institutions, and 24 stocks have the potential to rise more than 20% (with shares) Post date April 29, 2022 — 15:29 Post Lock Read More Zheshang CSI 500 Index Enhanced A Net Worth Down 5.95% Post date April 26, 2022 — 06:55 Post Lock Read More Caisuo Third-generation insulin revenue doubled, why is Tonghua Dongbao's share price still bottoming out? Interface News · Securities Post date April 21, 2022 — 09:05 Post Lock Read More Caisuo The third-generation insulin revenue doubled, why is Tonghua Dongbao's share price still bottoming out? Post date April 21, 2022 — 09:05 Post Lock Read More Third-generation insulin revenue doubled, why is Tonghua Dongbao's share price still bottoming out? Tonghua Dongbao_Sina Finance_Sina.com Post date April 21, 2022 — 09:03 Post Lock Read More Huatai Research Morning Star 20220420 Post date April 20, 2022 — 08:32 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
A-Share Toutiao Listed Company (5.10) Stock Financial Industry Post date May 10, 2022 — 00:03 Post Lock Read More On the evening of May 9th, Shanghai and Shenzhen listed companies announced the latest express of major events_ Oriental Fortune Net Post date May 9, 2022 — 19:55 Post Lock Read More Tonghua Dongbao: As some of the company's R&D projects have successively reached the capitalization conditions, the proportion of the company's R&D capitalization expenditure has increased in recent years. Post date May 5, 2022 — 15:16 Post Lock Read More Tonghua Dongbao: The company is confident to maintain the steady growth of second-generation insulin this year and will focus on the third-generation insulin market. Post date May 5, 2022 — 15:16 Post Lock Read More Tonghua Dongbao: As some of the company's R&D projects have successively reached the capitalization conditions, the proportion of the company's R&D capitalization expenditure has increased in recent years. Post date May 5, 2022 — 15:15 Post Lock Read More Tonghua Dongbao: The company accounted for 26.11% of the agreed procurement volume in Henan Province, ranking first in every economic network. Post date May 5, 2022 — 15:11 Post Lock Read More Tonghua Dongbao: In Henan Province, the company accounted for 26.11% of the agreed procurement volume of centralized procurement, occupying the first place – yqqlm Post date May 5, 2022 — 15:11 Post Lock Read More Tonghua Dongbao: In Henan Province, the company accounts for 26.11% of the agreed procurement volume of centralized procurement, occupying the first place_ Oriental Fortune Net Post date May 5, 2022 — 15:10 Post Lock Read More Can insulin "price-for-volume" bring new revenue? Before the answer was revealed, Gan & Lee Pharmaceutical went overseas to find new profit growth points. Post date May 1, 2022 — 00:19 Post Lock Read More The truth in the financial report: Can the "price-for-volume" of insulin in the pharmaceutical industry bring about new revenue growth? Before the answer was revealed, Gan & Lee Pharmaceutical went overseas to find new profit growth points. Post date May 1, 2022 — 00:16 Post Lock Read More Can insulin "price-for-volume" bring new revenue? Before the answer was revealed, Gan & Lee Pharmaceutical went overseas to find new profit growth points_Oriental Fortune Net Post date April 30, 2022 — 22:19 Post Lock Read More The truth in the financial report: Can the "price-for-volume" of insulin in the pharmaceutical industry bring about new revenue growth? Before the answer was revealed, Gan & Lee Pharmaceutical went overseas to find new profit growth points. Post date April 30, 2022 — 22:16 Post Lock Read More The truth in the financial report: Can the "price-for-volume" of insulin in the pharmaceutical industry bring about new revenue growth? Before the answer was announced, Gan & Lee Pharmaceutical went overseas to find new profit growth points Post date April 30, 2022 — 22:16 Post Lock Read More Thousands of listed companies have collectively disclosed their performance, and these 28 stocks are most favored by institutions! Many industry leaders are optimistic about the institutions, and 24 stocks have the potential to rise more than 20% (with shares) Post date April 29, 2022 — 15:29 Post Lock Read More Zheshang CSI 500 Index Enhanced A Net Worth Down 5.95% Post date April 26, 2022 — 06:55 Post Lock Read More Caisuo Third-generation insulin revenue doubled, why is Tonghua Dongbao's share price still bottoming out? Interface News · Securities Post date April 21, 2022 — 09:05 Post Lock Read More Caisuo The third-generation insulin revenue doubled, why is Tonghua Dongbao's share price still bottoming out? Post date April 21, 2022 — 09:05 Post Lock Read More Third-generation insulin revenue doubled, why is Tonghua Dongbao's share price still bottoming out? Tonghua Dongbao_Sina Finance_Sina.com Post date April 21, 2022 — 09:03 Post Lock Read More Huatai Research Morning Star 20220420 Post date April 20, 2022 — 08:32 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
On the evening of May 9th, Shanghai and Shenzhen listed companies announced the latest express of major events_ Oriental Fortune Net Post date May 9, 2022 — 19:55 Post Lock Read More Tonghua Dongbao: As some of the company's R&D projects have successively reached the capitalization conditions, the proportion of the company's R&D capitalization expenditure has increased in recent years. Post date May 5, 2022 — 15:16 Post Lock Read More Tonghua Dongbao: The company is confident to maintain the steady growth of second-generation insulin this year and will focus on the third-generation insulin market. Post date May 5, 2022 — 15:16 Post Lock Read More Tonghua Dongbao: As some of the company's R&D projects have successively reached the capitalization conditions, the proportion of the company's R&D capitalization expenditure has increased in recent years. Post date May 5, 2022 — 15:15 Post Lock Read More Tonghua Dongbao: The company accounted for 26.11% of the agreed procurement volume in Henan Province, ranking first in every economic network. Post date May 5, 2022 — 15:11 Post Lock Read More Tonghua Dongbao: In Henan Province, the company accounted for 26.11% of the agreed procurement volume of centralized procurement, occupying the first place – yqqlm Post date May 5, 2022 — 15:11 Post Lock Read More Tonghua Dongbao: In Henan Province, the company accounts for 26.11% of the agreed procurement volume of centralized procurement, occupying the first place_ Oriental Fortune Net Post date May 5, 2022 — 15:10 Post Lock Read More Can insulin "price-for-volume" bring new revenue? Before the answer was revealed, Gan & Lee Pharmaceutical went overseas to find new profit growth points. Post date May 1, 2022 — 00:19 Post Lock Read More The truth in the financial report: Can the "price-for-volume" of insulin in the pharmaceutical industry bring about new revenue growth? Before the answer was revealed, Gan & Lee Pharmaceutical went overseas to find new profit growth points. Post date May 1, 2022 — 00:16 Post Lock Read More Can insulin "price-for-volume" bring new revenue? Before the answer was revealed, Gan & Lee Pharmaceutical went overseas to find new profit growth points_Oriental Fortune Net Post date April 30, 2022 — 22:19 Post Lock Read More The truth in the financial report: Can the "price-for-volume" of insulin in the pharmaceutical industry bring about new revenue growth? Before the answer was revealed, Gan & Lee Pharmaceutical went overseas to find new profit growth points. Post date April 30, 2022 — 22:16 Post Lock Read More The truth in the financial report: Can the "price-for-volume" of insulin in the pharmaceutical industry bring about new revenue growth? Before the answer was announced, Gan & Lee Pharmaceutical went overseas to find new profit growth points Post date April 30, 2022 — 22:16 Post Lock Read More Thousands of listed companies have collectively disclosed their performance, and these 28 stocks are most favored by institutions! Many industry leaders are optimistic about the institutions, and 24 stocks have the potential to rise more than 20% (with shares) Post date April 29, 2022 — 15:29 Post Lock Read More Zheshang CSI 500 Index Enhanced A Net Worth Down 5.95% Post date April 26, 2022 — 06:55 Post Lock Read More Caisuo Third-generation insulin revenue doubled, why is Tonghua Dongbao's share price still bottoming out? Interface News · Securities Post date April 21, 2022 — 09:05 Post Lock Read More Caisuo The third-generation insulin revenue doubled, why is Tonghua Dongbao's share price still bottoming out? Post date April 21, 2022 — 09:05 Post Lock Read More Third-generation insulin revenue doubled, why is Tonghua Dongbao's share price still bottoming out? Tonghua Dongbao_Sina Finance_Sina.com Post date April 21, 2022 — 09:03 Post Lock Read More Huatai Research Morning Star 20220420 Post date April 20, 2022 — 08:32 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Tonghua Dongbao: As some of the company's R&D projects have successively reached the capitalization conditions, the proportion of the company's R&D capitalization expenditure has increased in recent years. Post date May 5, 2022 — 15:16 Post Lock Read More Tonghua Dongbao: The company is confident to maintain the steady growth of second-generation insulin this year and will focus on the third-generation insulin market. Post date May 5, 2022 — 15:16 Post Lock Read More Tonghua Dongbao: As some of the company's R&D projects have successively reached the capitalization conditions, the proportion of the company's R&D capitalization expenditure has increased in recent years. Post date May 5, 2022 — 15:15 Post Lock Read More Tonghua Dongbao: The company accounted for 26.11% of the agreed procurement volume in Henan Province, ranking first in every economic network. Post date May 5, 2022 — 15:11 Post Lock Read More Tonghua Dongbao: In Henan Province, the company accounted for 26.11% of the agreed procurement volume of centralized procurement, occupying the first place – yqqlm Post date May 5, 2022 — 15:11 Post Lock Read More Tonghua Dongbao: In Henan Province, the company accounts for 26.11% of the agreed procurement volume of centralized procurement, occupying the first place_ Oriental Fortune Net Post date May 5, 2022 — 15:10 Post Lock Read More Can insulin "price-for-volume" bring new revenue? Before the answer was revealed, Gan & Lee Pharmaceutical went overseas to find new profit growth points. Post date May 1, 2022 — 00:19 Post Lock Read More The truth in the financial report: Can the "price-for-volume" of insulin in the pharmaceutical industry bring about new revenue growth? Before the answer was revealed, Gan & Lee Pharmaceutical went overseas to find new profit growth points. Post date May 1, 2022 — 00:16 Post Lock Read More Can insulin "price-for-volume" bring new revenue? Before the answer was revealed, Gan & Lee Pharmaceutical went overseas to find new profit growth points_Oriental Fortune Net Post date April 30, 2022 — 22:19 Post Lock Read More The truth in the financial report: Can the "price-for-volume" of insulin in the pharmaceutical industry bring about new revenue growth? Before the answer was revealed, Gan & Lee Pharmaceutical went overseas to find new profit growth points. Post date April 30, 2022 — 22:16 Post Lock Read More The truth in the financial report: Can the "price-for-volume" of insulin in the pharmaceutical industry bring about new revenue growth? Before the answer was announced, Gan & Lee Pharmaceutical went overseas to find new profit growth points Post date April 30, 2022 — 22:16 Post Lock Read More Thousands of listed companies have collectively disclosed their performance, and these 28 stocks are most favored by institutions! Many industry leaders are optimistic about the institutions, and 24 stocks have the potential to rise more than 20% (with shares) Post date April 29, 2022 — 15:29 Post Lock Read More Zheshang CSI 500 Index Enhanced A Net Worth Down 5.95% Post date April 26, 2022 — 06:55 Post Lock Read More Caisuo Third-generation insulin revenue doubled, why is Tonghua Dongbao's share price still bottoming out? Interface News · Securities Post date April 21, 2022 — 09:05 Post Lock Read More Caisuo The third-generation insulin revenue doubled, why is Tonghua Dongbao's share price still bottoming out? Post date April 21, 2022 — 09:05 Post Lock Read More Third-generation insulin revenue doubled, why is Tonghua Dongbao's share price still bottoming out? Tonghua Dongbao_Sina Finance_Sina.com Post date April 21, 2022 — 09:03 Post Lock Read More Huatai Research Morning Star 20220420 Post date April 20, 2022 — 08:32 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Tonghua Dongbao: The company is confident to maintain the steady growth of second-generation insulin this year and will focus on the third-generation insulin market. Post date May 5, 2022 — 15:16 Post Lock Read More Tonghua Dongbao: As some of the company's R&D projects have successively reached the capitalization conditions, the proportion of the company's R&D capitalization expenditure has increased in recent years. Post date May 5, 2022 — 15:15 Post Lock Read More Tonghua Dongbao: The company accounted for 26.11% of the agreed procurement volume in Henan Province, ranking first in every economic network. Post date May 5, 2022 — 15:11 Post Lock Read More Tonghua Dongbao: In Henan Province, the company accounted for 26.11% of the agreed procurement volume of centralized procurement, occupying the first place – yqqlm Post date May 5, 2022 — 15:11 Post Lock Read More Tonghua Dongbao: In Henan Province, the company accounts for 26.11% of the agreed procurement volume of centralized procurement, occupying the first place_ Oriental Fortune Net Post date May 5, 2022 — 15:10 Post Lock Read More Can insulin "price-for-volume" bring new revenue? Before the answer was revealed, Gan & Lee Pharmaceutical went overseas to find new profit growth points. Post date May 1, 2022 — 00:19 Post Lock Read More The truth in the financial report: Can the "price-for-volume" of insulin in the pharmaceutical industry bring about new revenue growth? Before the answer was revealed, Gan & Lee Pharmaceutical went overseas to find new profit growth points. Post date May 1, 2022 — 00:16 Post Lock Read More Can insulin "price-for-volume" bring new revenue? Before the answer was revealed, Gan & Lee Pharmaceutical went overseas to find new profit growth points_Oriental Fortune Net Post date April 30, 2022 — 22:19 Post Lock Read More The truth in the financial report: Can the "price-for-volume" of insulin in the pharmaceutical industry bring about new revenue growth? Before the answer was revealed, Gan & Lee Pharmaceutical went overseas to find new profit growth points. Post date April 30, 2022 — 22:16 Post Lock Read More The truth in the financial report: Can the "price-for-volume" of insulin in the pharmaceutical industry bring about new revenue growth? Before the answer was announced, Gan & Lee Pharmaceutical went overseas to find new profit growth points Post date April 30, 2022 — 22:16 Post Lock Read More Thousands of listed companies have collectively disclosed their performance, and these 28 stocks are most favored by institutions! Many industry leaders are optimistic about the institutions, and 24 stocks have the potential to rise more than 20% (with shares) Post date April 29, 2022 — 15:29 Post Lock Read More Zheshang CSI 500 Index Enhanced A Net Worth Down 5.95% Post date April 26, 2022 — 06:55 Post Lock Read More Caisuo Third-generation insulin revenue doubled, why is Tonghua Dongbao's share price still bottoming out? Interface News · Securities Post date April 21, 2022 — 09:05 Post Lock Read More Caisuo The third-generation insulin revenue doubled, why is Tonghua Dongbao's share price still bottoming out? Post date April 21, 2022 — 09:05 Post Lock Read More Third-generation insulin revenue doubled, why is Tonghua Dongbao's share price still bottoming out? Tonghua Dongbao_Sina Finance_Sina.com Post date April 21, 2022 — 09:03 Post Lock Read More Huatai Research Morning Star 20220420 Post date April 20, 2022 — 08:32 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Tonghua Dongbao: As some of the company's R&D projects have successively reached the capitalization conditions, the proportion of the company's R&D capitalization expenditure has increased in recent years. Post date May 5, 2022 — 15:15 Post Lock Read More Tonghua Dongbao: The company accounted for 26.11% of the agreed procurement volume in Henan Province, ranking first in every economic network. Post date May 5, 2022 — 15:11 Post Lock Read More Tonghua Dongbao: In Henan Province, the company accounted for 26.11% of the agreed procurement volume of centralized procurement, occupying the first place – yqqlm Post date May 5, 2022 — 15:11 Post Lock Read More Tonghua Dongbao: In Henan Province, the company accounts for 26.11% of the agreed procurement volume of centralized procurement, occupying the first place_ Oriental Fortune Net Post date May 5, 2022 — 15:10 Post Lock Read More Can insulin "price-for-volume" bring new revenue? Before the answer was revealed, Gan & Lee Pharmaceutical went overseas to find new profit growth points. Post date May 1, 2022 — 00:19 Post Lock Read More The truth in the financial report: Can the "price-for-volume" of insulin in the pharmaceutical industry bring about new revenue growth? Before the answer was revealed, Gan & Lee Pharmaceutical went overseas to find new profit growth points. Post date May 1, 2022 — 00:16 Post Lock Read More Can insulin "price-for-volume" bring new revenue? Before the answer was revealed, Gan & Lee Pharmaceutical went overseas to find new profit growth points_Oriental Fortune Net Post date April 30, 2022 — 22:19 Post Lock Read More The truth in the financial report: Can the "price-for-volume" of insulin in the pharmaceutical industry bring about new revenue growth? Before the answer was revealed, Gan & Lee Pharmaceutical went overseas to find new profit growth points. Post date April 30, 2022 — 22:16 Post Lock Read More The truth in the financial report: Can the "price-for-volume" of insulin in the pharmaceutical industry bring about new revenue growth? Before the answer was announced, Gan & Lee Pharmaceutical went overseas to find new profit growth points Post date April 30, 2022 — 22:16 Post Lock Read More Thousands of listed companies have collectively disclosed their performance, and these 28 stocks are most favored by institutions! Many industry leaders are optimistic about the institutions, and 24 stocks have the potential to rise more than 20% (with shares) Post date April 29, 2022 — 15:29 Post Lock Read More Zheshang CSI 500 Index Enhanced A Net Worth Down 5.95% Post date April 26, 2022 — 06:55 Post Lock Read More Caisuo Third-generation insulin revenue doubled, why is Tonghua Dongbao's share price still bottoming out? Interface News · Securities Post date April 21, 2022 — 09:05 Post Lock Read More Caisuo The third-generation insulin revenue doubled, why is Tonghua Dongbao's share price still bottoming out? Post date April 21, 2022 — 09:05 Post Lock Read More Third-generation insulin revenue doubled, why is Tonghua Dongbao's share price still bottoming out? Tonghua Dongbao_Sina Finance_Sina.com Post date April 21, 2022 — 09:03 Post Lock Read More Huatai Research Morning Star 20220420 Post date April 20, 2022 — 08:32 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Tonghua Dongbao: The company accounted for 26.11% of the agreed procurement volume in Henan Province, ranking first in every economic network. Post date May 5, 2022 — 15:11 Post Lock Read More Tonghua Dongbao: In Henan Province, the company accounted for 26.11% of the agreed procurement volume of centralized procurement, occupying the first place – yqqlm Post date May 5, 2022 — 15:11 Post Lock Read More Tonghua Dongbao: In Henan Province, the company accounts for 26.11% of the agreed procurement volume of centralized procurement, occupying the first place_ Oriental Fortune Net Post date May 5, 2022 — 15:10 Post Lock Read More Can insulin "price-for-volume" bring new revenue? Before the answer was revealed, Gan & Lee Pharmaceutical went overseas to find new profit growth points. Post date May 1, 2022 — 00:19 Post Lock Read More The truth in the financial report: Can the "price-for-volume" of insulin in the pharmaceutical industry bring about new revenue growth? Before the answer was revealed, Gan & Lee Pharmaceutical went overseas to find new profit growth points. Post date May 1, 2022 — 00:16 Post Lock Read More Can insulin "price-for-volume" bring new revenue? Before the answer was revealed, Gan & Lee Pharmaceutical went overseas to find new profit growth points_Oriental Fortune Net Post date April 30, 2022 — 22:19 Post Lock Read More The truth in the financial report: Can the "price-for-volume" of insulin in the pharmaceutical industry bring about new revenue growth? Before the answer was revealed, Gan & Lee Pharmaceutical went overseas to find new profit growth points. Post date April 30, 2022 — 22:16 Post Lock Read More The truth in the financial report: Can the "price-for-volume" of insulin in the pharmaceutical industry bring about new revenue growth? Before the answer was announced, Gan & Lee Pharmaceutical went overseas to find new profit growth points Post date April 30, 2022 — 22:16 Post Lock Read More Thousands of listed companies have collectively disclosed their performance, and these 28 stocks are most favored by institutions! Many industry leaders are optimistic about the institutions, and 24 stocks have the potential to rise more than 20% (with shares) Post date April 29, 2022 — 15:29 Post Lock Read More Zheshang CSI 500 Index Enhanced A Net Worth Down 5.95% Post date April 26, 2022 — 06:55 Post Lock Read More Caisuo Third-generation insulin revenue doubled, why is Tonghua Dongbao's share price still bottoming out? Interface News · Securities Post date April 21, 2022 — 09:05 Post Lock Read More Caisuo The third-generation insulin revenue doubled, why is Tonghua Dongbao's share price still bottoming out? Post date April 21, 2022 — 09:05 Post Lock Read More Third-generation insulin revenue doubled, why is Tonghua Dongbao's share price still bottoming out? Tonghua Dongbao_Sina Finance_Sina.com Post date April 21, 2022 — 09:03 Post Lock Read More Huatai Research Morning Star 20220420 Post date April 20, 2022 — 08:32 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Tonghua Dongbao: In Henan Province, the company accounted for 26.11% of the agreed procurement volume of centralized procurement, occupying the first place – yqqlm Post date May 5, 2022 — 15:11 Post Lock Read More Tonghua Dongbao: In Henan Province, the company accounts for 26.11% of the agreed procurement volume of centralized procurement, occupying the first place_ Oriental Fortune Net Post date May 5, 2022 — 15:10 Post Lock Read More Can insulin "price-for-volume" bring new revenue? Before the answer was revealed, Gan & Lee Pharmaceutical went overseas to find new profit growth points. Post date May 1, 2022 — 00:19 Post Lock Read More The truth in the financial report: Can the "price-for-volume" of insulin in the pharmaceutical industry bring about new revenue growth? Before the answer was revealed, Gan & Lee Pharmaceutical went overseas to find new profit growth points. Post date May 1, 2022 — 00:16 Post Lock Read More Can insulin "price-for-volume" bring new revenue? Before the answer was revealed, Gan & Lee Pharmaceutical went overseas to find new profit growth points_Oriental Fortune Net Post date April 30, 2022 — 22:19 Post Lock Read More The truth in the financial report: Can the "price-for-volume" of insulin in the pharmaceutical industry bring about new revenue growth? Before the answer was revealed, Gan & Lee Pharmaceutical went overseas to find new profit growth points. Post date April 30, 2022 — 22:16 Post Lock Read More The truth in the financial report: Can the "price-for-volume" of insulin in the pharmaceutical industry bring about new revenue growth? Before the answer was announced, Gan & Lee Pharmaceutical went overseas to find new profit growth points Post date April 30, 2022 — 22:16 Post Lock Read More Thousands of listed companies have collectively disclosed their performance, and these 28 stocks are most favored by institutions! Many industry leaders are optimistic about the institutions, and 24 stocks have the potential to rise more than 20% (with shares) Post date April 29, 2022 — 15:29 Post Lock Read More Zheshang CSI 500 Index Enhanced A Net Worth Down 5.95% Post date April 26, 2022 — 06:55 Post Lock Read More Caisuo Third-generation insulin revenue doubled, why is Tonghua Dongbao's share price still bottoming out? Interface News · Securities Post date April 21, 2022 — 09:05 Post Lock Read More Caisuo The third-generation insulin revenue doubled, why is Tonghua Dongbao's share price still bottoming out? Post date April 21, 2022 — 09:05 Post Lock Read More Third-generation insulin revenue doubled, why is Tonghua Dongbao's share price still bottoming out? Tonghua Dongbao_Sina Finance_Sina.com Post date April 21, 2022 — 09:03 Post Lock Read More Huatai Research Morning Star 20220420 Post date April 20, 2022 — 08:32 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Tonghua Dongbao: In Henan Province, the company accounts for 26.11% of the agreed procurement volume of centralized procurement, occupying the first place_ Oriental Fortune Net Post date May 5, 2022 — 15:10 Post Lock Read More Can insulin "price-for-volume" bring new revenue? Before the answer was revealed, Gan & Lee Pharmaceutical went overseas to find new profit growth points. Post date May 1, 2022 — 00:19 Post Lock Read More The truth in the financial report: Can the "price-for-volume" of insulin in the pharmaceutical industry bring about new revenue growth? Before the answer was revealed, Gan & Lee Pharmaceutical went overseas to find new profit growth points. Post date May 1, 2022 — 00:16 Post Lock Read More Can insulin "price-for-volume" bring new revenue? Before the answer was revealed, Gan & Lee Pharmaceutical went overseas to find new profit growth points_Oriental Fortune Net Post date April 30, 2022 — 22:19 Post Lock Read More The truth in the financial report: Can the "price-for-volume" of insulin in the pharmaceutical industry bring about new revenue growth? Before the answer was revealed, Gan & Lee Pharmaceutical went overseas to find new profit growth points. Post date April 30, 2022 — 22:16 Post Lock Read More The truth in the financial report: Can the "price-for-volume" of insulin in the pharmaceutical industry bring about new revenue growth? Before the answer was announced, Gan & Lee Pharmaceutical went overseas to find new profit growth points Post date April 30, 2022 — 22:16 Post Lock Read More Thousands of listed companies have collectively disclosed their performance, and these 28 stocks are most favored by institutions! Many industry leaders are optimistic about the institutions, and 24 stocks have the potential to rise more than 20% (with shares) Post date April 29, 2022 — 15:29 Post Lock Read More Zheshang CSI 500 Index Enhanced A Net Worth Down 5.95% Post date April 26, 2022 — 06:55 Post Lock Read More Caisuo Third-generation insulin revenue doubled, why is Tonghua Dongbao's share price still bottoming out? Interface News · Securities Post date April 21, 2022 — 09:05 Post Lock Read More Caisuo The third-generation insulin revenue doubled, why is Tonghua Dongbao's share price still bottoming out? Post date April 21, 2022 — 09:05 Post Lock Read More Third-generation insulin revenue doubled, why is Tonghua Dongbao's share price still bottoming out? Tonghua Dongbao_Sina Finance_Sina.com Post date April 21, 2022 — 09:03 Post Lock Read More Huatai Research Morning Star 20220420 Post date April 20, 2022 — 08:32 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Can insulin "price-for-volume" bring new revenue? Before the answer was revealed, Gan & Lee Pharmaceutical went overseas to find new profit growth points. Post date May 1, 2022 — 00:19 Post Lock Read More The truth in the financial report: Can the "price-for-volume" of insulin in the pharmaceutical industry bring about new revenue growth? Before the answer was revealed, Gan & Lee Pharmaceutical went overseas to find new profit growth points. Post date May 1, 2022 — 00:16 Post Lock Read More Can insulin "price-for-volume" bring new revenue? Before the answer was revealed, Gan & Lee Pharmaceutical went overseas to find new profit growth points_Oriental Fortune Net Post date April 30, 2022 — 22:19 Post Lock Read More The truth in the financial report: Can the "price-for-volume" of insulin in the pharmaceutical industry bring about new revenue growth? Before the answer was revealed, Gan & Lee Pharmaceutical went overseas to find new profit growth points. Post date April 30, 2022 — 22:16 Post Lock Read More The truth in the financial report: Can the "price-for-volume" of insulin in the pharmaceutical industry bring about new revenue growth? Before the answer was announced, Gan & Lee Pharmaceutical went overseas to find new profit growth points Post date April 30, 2022 — 22:16 Post Lock Read More Thousands of listed companies have collectively disclosed their performance, and these 28 stocks are most favored by institutions! Many industry leaders are optimistic about the institutions, and 24 stocks have the potential to rise more than 20% (with shares) Post date April 29, 2022 — 15:29 Post Lock Read More Zheshang CSI 500 Index Enhanced A Net Worth Down 5.95% Post date April 26, 2022 — 06:55 Post Lock Read More Caisuo Third-generation insulin revenue doubled, why is Tonghua Dongbao's share price still bottoming out? Interface News · Securities Post date April 21, 2022 — 09:05 Post Lock Read More Caisuo The third-generation insulin revenue doubled, why is Tonghua Dongbao's share price still bottoming out? Post date April 21, 2022 — 09:05 Post Lock Read More Third-generation insulin revenue doubled, why is Tonghua Dongbao's share price still bottoming out? Tonghua Dongbao_Sina Finance_Sina.com Post date April 21, 2022 — 09:03 Post Lock Read More Huatai Research Morning Star 20220420 Post date April 20, 2022 — 08:32 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
The truth in the financial report: Can the "price-for-volume" of insulin in the pharmaceutical industry bring about new revenue growth? Before the answer was revealed, Gan & Lee Pharmaceutical went overseas to find new profit growth points. Post date May 1, 2022 — 00:16 Post Lock Read More Can insulin "price-for-volume" bring new revenue? Before the answer was revealed, Gan & Lee Pharmaceutical went overseas to find new profit growth points_Oriental Fortune Net Post date April 30, 2022 — 22:19 Post Lock Read More The truth in the financial report: Can the "price-for-volume" of insulin in the pharmaceutical industry bring about new revenue growth? Before the answer was revealed, Gan & Lee Pharmaceutical went overseas to find new profit growth points. Post date April 30, 2022 — 22:16 Post Lock Read More The truth in the financial report: Can the "price-for-volume" of insulin in the pharmaceutical industry bring about new revenue growth? Before the answer was announced, Gan & Lee Pharmaceutical went overseas to find new profit growth points Post date April 30, 2022 — 22:16 Post Lock Read More Thousands of listed companies have collectively disclosed their performance, and these 28 stocks are most favored by institutions! Many industry leaders are optimistic about the institutions, and 24 stocks have the potential to rise more than 20% (with shares) Post date April 29, 2022 — 15:29 Post Lock Read More Zheshang CSI 500 Index Enhanced A Net Worth Down 5.95% Post date April 26, 2022 — 06:55 Post Lock Read More Caisuo Third-generation insulin revenue doubled, why is Tonghua Dongbao's share price still bottoming out? Interface News · Securities Post date April 21, 2022 — 09:05 Post Lock Read More Caisuo The third-generation insulin revenue doubled, why is Tonghua Dongbao's share price still bottoming out? Post date April 21, 2022 — 09:05 Post Lock Read More Third-generation insulin revenue doubled, why is Tonghua Dongbao's share price still bottoming out? Tonghua Dongbao_Sina Finance_Sina.com Post date April 21, 2022 — 09:03 Post Lock Read More Huatai Research Morning Star 20220420 Post date April 20, 2022 — 08:32 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Can insulin "price-for-volume" bring new revenue? Before the answer was revealed, Gan & Lee Pharmaceutical went overseas to find new profit growth points_Oriental Fortune Net Post date April 30, 2022 — 22:19 Post Lock Read More The truth in the financial report: Can the "price-for-volume" of insulin in the pharmaceutical industry bring about new revenue growth? Before the answer was revealed, Gan & Lee Pharmaceutical went overseas to find new profit growth points. Post date April 30, 2022 — 22:16 Post Lock Read More The truth in the financial report: Can the "price-for-volume" of insulin in the pharmaceutical industry bring about new revenue growth? Before the answer was announced, Gan & Lee Pharmaceutical went overseas to find new profit growth points Post date April 30, 2022 — 22:16 Post Lock Read More Thousands of listed companies have collectively disclosed their performance, and these 28 stocks are most favored by institutions! Many industry leaders are optimistic about the institutions, and 24 stocks have the potential to rise more than 20% (with shares) Post date April 29, 2022 — 15:29 Post Lock Read More Zheshang CSI 500 Index Enhanced A Net Worth Down 5.95% Post date April 26, 2022 — 06:55 Post Lock Read More Caisuo Third-generation insulin revenue doubled, why is Tonghua Dongbao's share price still bottoming out? Interface News · Securities Post date April 21, 2022 — 09:05 Post Lock Read More Caisuo The third-generation insulin revenue doubled, why is Tonghua Dongbao's share price still bottoming out? Post date April 21, 2022 — 09:05 Post Lock Read More Third-generation insulin revenue doubled, why is Tonghua Dongbao's share price still bottoming out? Tonghua Dongbao_Sina Finance_Sina.com Post date April 21, 2022 — 09:03 Post Lock Read More Huatai Research Morning Star 20220420 Post date April 20, 2022 — 08:32 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
The truth in the financial report: Can the "price-for-volume" of insulin in the pharmaceutical industry bring about new revenue growth? Before the answer was revealed, Gan & Lee Pharmaceutical went overseas to find new profit growth points. Post date April 30, 2022 — 22:16 Post Lock Read More The truth in the financial report: Can the "price-for-volume" of insulin in the pharmaceutical industry bring about new revenue growth? Before the answer was announced, Gan & Lee Pharmaceutical went overseas to find new profit growth points Post date April 30, 2022 — 22:16 Post Lock Read More Thousands of listed companies have collectively disclosed their performance, and these 28 stocks are most favored by institutions! Many industry leaders are optimistic about the institutions, and 24 stocks have the potential to rise more than 20% (with shares) Post date April 29, 2022 — 15:29 Post Lock Read More Zheshang CSI 500 Index Enhanced A Net Worth Down 5.95% Post date April 26, 2022 — 06:55 Post Lock Read More Caisuo Third-generation insulin revenue doubled, why is Tonghua Dongbao's share price still bottoming out? Interface News · Securities Post date April 21, 2022 — 09:05 Post Lock Read More Caisuo The third-generation insulin revenue doubled, why is Tonghua Dongbao's share price still bottoming out? Post date April 21, 2022 — 09:05 Post Lock Read More Third-generation insulin revenue doubled, why is Tonghua Dongbao's share price still bottoming out? Tonghua Dongbao_Sina Finance_Sina.com Post date April 21, 2022 — 09:03 Post Lock Read More Huatai Research Morning Star 20220420 Post date April 20, 2022 — 08:32 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
The truth in the financial report: Can the "price-for-volume" of insulin in the pharmaceutical industry bring about new revenue growth? Before the answer was announced, Gan & Lee Pharmaceutical went overseas to find new profit growth points Post date April 30, 2022 — 22:16 Post Lock Read More Thousands of listed companies have collectively disclosed their performance, and these 28 stocks are most favored by institutions! Many industry leaders are optimistic about the institutions, and 24 stocks have the potential to rise more than 20% (with shares) Post date April 29, 2022 — 15:29 Post Lock Read More Zheshang CSI 500 Index Enhanced A Net Worth Down 5.95% Post date April 26, 2022 — 06:55 Post Lock Read More Caisuo Third-generation insulin revenue doubled, why is Tonghua Dongbao's share price still bottoming out? Interface News · Securities Post date April 21, 2022 — 09:05 Post Lock Read More Caisuo The third-generation insulin revenue doubled, why is Tonghua Dongbao's share price still bottoming out? Post date April 21, 2022 — 09:05 Post Lock Read More Third-generation insulin revenue doubled, why is Tonghua Dongbao's share price still bottoming out? Tonghua Dongbao_Sina Finance_Sina.com Post date April 21, 2022 — 09:03 Post Lock Read More Huatai Research Morning Star 20220420 Post date April 20, 2022 — 08:32 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Thousands of listed companies have collectively disclosed their performance, and these 28 stocks are most favored by institutions! Many industry leaders are optimistic about the institutions, and 24 stocks have the potential to rise more than 20% (with shares) Post date April 29, 2022 — 15:29 Post Lock Read More Zheshang CSI 500 Index Enhanced A Net Worth Down 5.95% Post date April 26, 2022 — 06:55 Post Lock Read More Caisuo Third-generation insulin revenue doubled, why is Tonghua Dongbao's share price still bottoming out? Interface News · Securities Post date April 21, 2022 — 09:05 Post Lock Read More Caisuo The third-generation insulin revenue doubled, why is Tonghua Dongbao's share price still bottoming out? Post date April 21, 2022 — 09:05 Post Lock Read More Third-generation insulin revenue doubled, why is Tonghua Dongbao's share price still bottoming out? Tonghua Dongbao_Sina Finance_Sina.com Post date April 21, 2022 — 09:03 Post Lock Read More Huatai Research Morning Star 20220420 Post date April 20, 2022 — 08:32 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Zheshang CSI 500 Index Enhanced A Net Worth Down 5.95% Post date April 26, 2022 — 06:55 Post Lock Read More Caisuo Third-generation insulin revenue doubled, why is Tonghua Dongbao's share price still bottoming out? Interface News · Securities Post date April 21, 2022 — 09:05 Post Lock Read More Caisuo The third-generation insulin revenue doubled, why is Tonghua Dongbao's share price still bottoming out? Post date April 21, 2022 — 09:05 Post Lock Read More Third-generation insulin revenue doubled, why is Tonghua Dongbao's share price still bottoming out? Tonghua Dongbao_Sina Finance_Sina.com Post date April 21, 2022 — 09:03 Post Lock Read More Huatai Research Morning Star 20220420 Post date April 20, 2022 — 08:32 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Caisuo Third-generation insulin revenue doubled, why is Tonghua Dongbao's share price still bottoming out? Interface News · Securities Post date April 21, 2022 — 09:05 Post Lock Read More Caisuo The third-generation insulin revenue doubled, why is Tonghua Dongbao's share price still bottoming out? Post date April 21, 2022 — 09:05 Post Lock Read More Third-generation insulin revenue doubled, why is Tonghua Dongbao's share price still bottoming out? Tonghua Dongbao_Sina Finance_Sina.com Post date April 21, 2022 — 09:03 Post Lock Read More Huatai Research Morning Star 20220420 Post date April 20, 2022 — 08:32 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Caisuo The third-generation insulin revenue doubled, why is Tonghua Dongbao's share price still bottoming out? Post date April 21, 2022 — 09:05 Post Lock Read More Third-generation insulin revenue doubled, why is Tonghua Dongbao's share price still bottoming out? Tonghua Dongbao_Sina Finance_Sina.com Post date April 21, 2022 — 09:03 Post Lock Read More Huatai Research Morning Star 20220420 Post date April 20, 2022 — 08:32 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Third-generation insulin revenue doubled, why is Tonghua Dongbao's share price still bottoming out? Tonghua Dongbao_Sina Finance_Sina.com Post date April 21, 2022 — 09:03 Post Lock Read More Huatai Research Morning Star 20220420 Post date April 20, 2022 — 08:32 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Caishen.CoCaishen.Co